Asset Details
Do you wish to reserve the book?
The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction
Do you wish to request the book?
The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction
2011
Overview
Bivalirudin is commonly used during percutaneous coronary intervention (PCI) rather than unfractionated heparin. The higher cost of bivalirudin may be offset if it reduces costly bleeding complications and/or length of stay. We sought to assess the effect of using bivalirudin on the costs of care among patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI.
We analyzed data from 64,872 patients treated in 1 of 278 hospitals. The effect of overall hospital use of bivalirudin on clinical and economic outcomes was assessed using multivariable regression, based on average hospital use of treatments.
The use of bivalirudin among patients with STEMI treated with PCI varied widely across hospitals, with a median of 6.9% (interquartile range 2.3%-18.6%). After controlling for patient and hospital characteristics, use of bivalirudin rather than heparin and a glycoprotein IIb/IIIa inhibitor reduced bleeding (odds ratio 0.47,
P < .001), length of stay (−0.47 days,
P < .03), and hospital costs (−14%,
P < .04).
Use of bivalirudin among patients with STEMI treated with PCI appears to reduce bleeding and overall costs.
Publisher
Mosby, Inc,Mosby,Elsevier Limited
Subject
/ Angioplasty, Balloon, Coronary - adverse effects
/ Angioplasty, Balloon, Coronary - economics
/ Angioplasty, Balloon, Coronary - methods
/ Antithrombins - therapeutic use
/ Biological and medical sciences
/ Disease
/ Female
/ Heart
/ Hirudins
/ Humans
/ Male
/ Myocardial Infarction - economics
/ Myocardial Infarction - therapy
/ Myocarditis. Cardiomyopathies
/ Patients
/ Peptide Fragments - therapeutic use
/ Postoperative Hemorrhage - economics
/ Postoperative Hemorrhage - epidemiology
/ Postoperative Hemorrhage - prevention & control
